New Whitepaper: Origination in the Age of AI–How signal-driven infrastructure is replacing broker-dependent deal flow.Read now↗

PE Firms M&A Firms Commercial Lenders Investment Banks
Deal Origination
End-to-end outreach infrastructure that sources proprietary deal flow.
Data & Research
TAM mapping, data enrichment, custom scraping, and automated research.
Trigger Intelligence (Signals)
Signal-driven deal intelligence delivered to your CRM, Slack, and email.
Resources
Playbooks
Channel-specific outreach playbooks for deal origination.
All research
Comparison posts, methodology, and analysis from the Tentt team.
Reports
Monthly market reports on M&A and private equity activity.
Tools
Free calculators for M&A, lending, and deal analysis.
Whitepaper↗
Origination in the Age of AI.
About
Book an intro call

Ligand Pharmaceuticals — Acquisitions & M&A Deals

1 deal

Tracking 1 M&A deal by Ligand Pharmaceuticals.

Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator

Financial ServicesFloridaMerger

Ligand Pharmaceuticals→XOMA Royalty

Apr 27, 2026